First triazole synthetic antifungal agent. Used for treatment of various Candida infections, cryptococcal meningitis, and prophylaxis in BMT patients Associated with increased incidence of Candida krusei when used for prophylaxis.

Composition

Each capsule contains Fluconazole 150mg & 200mg (JP Specs).

Indication

FUZON is used: For the treatment of candidemia and invasive (non-CNS) candidiasis. For the treatment of oropharyngeal candidiasis (thrush). For the treatment of esophageal candidiasis. For the treatment of nonmeningeal, pulmonary or extrapulmonary cryptococcosis. For the treatment of pneumonia caused by Candida sp. For the treatment of intraabdominal infections (i.e., peritonitis, intraabdominal abscess) caused by Candida sp. For the treatment of urinary tract infection (UTI), including symptomatic cystitis, caused by Candida sp. (e.g., candiduria). For the treatment of pyelonephritis caused by Candida sp. For candidiasis prophylaxis in high-risk patients. For the treatment of cryptococcal meningitis. For the treatment of CNS infections, including meningitis. For the treatment of CNS infections due to Coccidioides sp. For the treatment of endophthalmitis caused by Candida sp. For the treatment of Candida infections of the cardiovascular system, including endocarditis, suppurative thrombophlebitis, and infected pacemaker, implantable cardiac defibrillator (ICD), or ventricular assist devices (VAD). For the treatment of bone and joint infections (i.e., osteomyelitis and infectious arthritis) caused by Candida sp. For the treatment of vulvovaginal candidiasis (VVC) and vulvovaginal candidiasis prophylaxis in patients with recurrent infections. For suppressive therapy for bacterial vaginosis. For the treatment of disseminated (nonmeningeal) or pulmonary blastomycosis. For the treatment of disseminated (non-meningeal) or pulmonary coccidioidomycosis. For primary coccidioidomycosis prophylaxis in HIV-infected patients. For the treatment of disseminated or pulmonary histoplasmosis in HIV-infected patients. For chronic suppressive therapy of histoplasmosis (i.e., secondary histoplasmosis prophylaxis) in HIV-infected patients. For primary penicilliosis prophylaxis in HIV-infected patients.